Cite

HARVARD Citation

    Taek Kim, J. et al. (2021). Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy. JCO precision oncology. p. . [Online]. 
  
Back to record